Neurobiology of Premature Ejaculation: Serotonergic Mechanisms and Emerging Therapeutic Insights

Abstract

Premature ejaculation (PE) is the most frequently reported male sexual dysfunction, characterized by a shortened intravaginal ejaculatory latency time (IELT), lack of control over ejaculation, and psychological distress. While PE involves multifactorial psychobiological factors, accumulating evidence emphasizes the pivotal role of serotonin (5-hydroxytryptamine, 5-HT) in modulating the ejaculatory reflex. This review summarizes the principal serotonergic mechanisms regulating IELT and their clinical implications to provide a cohesive mechanistic framework. Receptor-specific pathways are briefly outlined in Section 4 and discussed in detail in Sections 5–7. We also highlight genetic polymorphisms (e.g., 5-HTTLPR, HTR1A, and HTR2C) that affect 5-HT transport and receptor function, potentially predisposing individuals to PE. The therapeutic use of selective serotonin reuptake inhibitors (SSRIs) is reviewed, with emphasis on comparative clinical efficacy and guideline-based recommendations. Despite their utility, SSRIs are associated with adverse effects such as anorgasmia, emotional blunting, and withdrawal symptoms. Emerging receptor-selective agents and next-generation 5-HT modulators are also discussed for their potential to improve efficacy and tolerability. This review provides an integrated neurobiological and clinical perspective on PE, supporting the development of targeted, individualized therapies that optimize outcomes while minimizing side effects.